002022 Stock Overview
Researches and develops, produces, and sells in vitro diagnostic reagents and automatic analyzers in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 002022 from our risk checks.
Shanghai Kehua Bio-Engineering Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.73 |
| 52 Week High | CN¥11.85 |
| 52 Week Low | CN¥5.56 |
| Beta | 0.36 |
| 11 Month Change | -10.89% |
| 3 Month Change | -27.92% |
| 1 Year Change | -46.25% |
| 33 Year Change | -66.82% |
| 5 Year Change | -43.49% |
| Change since IPO | -74.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002022 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.9% | 0.007% | 0.6% |
| 1Y | -46.2% | -24.2% | -18.5% |
Return vs Industry: 002022 underperformed the CN Biotechs industry which returned -24.2% over the past year.
Return vs Market: 002022 underperformed the CN Market which returned -18.5% over the past year.
Price Volatility
| 002022 volatility | |
|---|---|
| 002022 Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002022's share price has been volatile over the past 3 months.
Volatility Over Time: 002022's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,151 | Ming Li | www.skhb.com |
Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic reagents and automatic analyzers in China. It offers signature products, including immunoassay & clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management, and automated comprehensive solutions for nucleic acid blood screening; and immunologic diagnosis products, such as KHB Polaris i1800 full-automatic chemiluminescence immunoassay analysis systems, Polaris i2400 fully automated chemiluminescence immunoassay analysis systems, enzyme linked immunosorbent assay kits, and microplate reader and plate washers. The company also provides biochemical diagnosis products, including ZY Series of automatic clinical chemistry analyzers, Polaris c1000 fully automated modular clinical chemistry analysis systems, and general packaging reagents; and molecular diagnostics products, such as nucleic acid extractors, PCR thermal cyclers, real-time PCR systems, automatic nucleic acid workstations, and compatible kits for extraction and detection; and KHB molecular diagnostics reagents, as well as KHB anti-HIV colloid gold products.
Shanghai Kehua Bio-Engineering Co.,Ltd Fundamentals Summary
| 002022 fundamental statistics | |
|---|---|
| Market cap | CN¥2.90b |
| Earnings (TTM) | -CN¥317.60m |
| Revenue (TTM) | CN¥2.04b |
1.4x
P/S Ratio-9.0x
P/E RatioIs 002022 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002022 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.04b |
| Cost of Revenue | CN¥1.31b |
| Gross Profit | CN¥730.38m |
| Other Expenses | CN¥1.05b |
| Earnings | -CN¥317.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 35.83% |
| Net Profit Margin | -15.58% |
| Debt/Equity Ratio | 18.0% |
How did 002022 perform over the long term?
See historical performance and comparison